July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

July 13, 2020

Initiation of New Phase III Clinical Study (AHEAD 3-45) of BAN2401 Preclinical (Asymptomatic) Alzheimer’s Disease

Cambridge, Mass.— Biogen Inc.  (Nasdaq:BIIB) today announced ... edit content here ---- Edit content here -----To access the live webcast, please go to the investors section of Biogen’s website at . Following the live webcast, an archived version of the call will be

July 8, 2020

The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS

Tofersen is an investigational molecule for superoxide dismutase 1 ( SOD1) amyotrophic lateral sclerosis (ALS), the second most common genetic form of ALS, a progressive neurodegenerative disease Final Phase 1/2 study results demonstrated proof-of-concept and proof-of-biology of tofersen, which is

July 8, 2020

Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease

If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease CAMBRIDGE, Mass. and TOKYO, July 08, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the

July 7, 2020

Biogen to Report Second Quarter 2020 Financial Results July 22, 2020

Cambridge, Mass.— Biogen Inc.  (Nasdaq:BIIB) today announced it will report second quarter 2020 financial results Wednesday, July 22, 2020, before the financial markets open.  Following the release of the financials, the Company will host a live webcast with Biogen management at 8:00 a.m. ET.

June 16, 2020

Biogen to Participate in SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that Chris Henderson, Ph.D., SVP, Head of Research, will participate in a live Q&A in SVB Leerink’s CybeRx Series: 2nd Annual CNS Forum. The webcast will be live on Tuesday, June 23, at 12:30 p.m. ET.

June 10, 2020

New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment

After up to 4.8 years of continuous treatment with SPINRAZA, 100 percent of children treated pre-symptomatically were alive, and none require permanent ventilation Patients continued to maintain and make progressive gains in motor function compared to the natural history of the disease, with 96

June 4, 2020

Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020

Full analysis of the CLE part of the LILAC study reinforces positive top-line results; participants who received BIIB059 (anti-BDCA2) demonstrated statistically significant reduction of disease activity compared to those who received placebo Safety and tolerability data further support the

May 28, 2020

Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science

The online learning program combines lab simulations and mentoring experiences focused on biotechnology and neurological diseases, such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis Four hundred students from Massachusetts and North Carolina are enrolling in this no-fee program

May 19, 2020

New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS

Patients treated with VUMERITY ® (diroximel fumarate) and TECFIDERA ® (dimethyl fumarate) showed a significant reduction of gadolinium-enhancing lesions compared to baseline Additional data show improved gastrointestinal tolerability with VUMERITY compared to TECFIDERA Further research evaluates

May 18, 2020

New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

Treatment with SPINRAZA improved or stabilized motor function across patient populations, including young adults The longer-term safety profile of SPINRAZA was consistent among a broad spectrum of ages and SMA types New data add to the significant body of evidence underscoring the clinically